Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708481 | 0.85 | HTT (0.56) | HTTALOX5SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL19091716 | 0.83 | ALDH1A1 (0.57) | ALOX5ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL15386974 | 0.83 | ALOX5 (0.47) | HTTALOX5SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4459739 | 0.82 | HTT (0.53) | HTTALOX5SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4002523 | 0.81 | ALDH1A1 (0.56) | HTTALOX5SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8566732 | 0.81 | ALOX5 (0.66) | HTTALOX5ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL15386986 | 0.81 | LMNA (0.50) | ALOX5ALDH1A1GAAPOLB | |
| SCHEMBL10048247 | 0.80 | SMN1; SMN2 (0.66) | ALOX5SMN1; SMN2 | |
| SCHEMBL2405257 | 0.80 | CCR5 (0.62) | HTTALOX5SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3628705 | 0.79 | HTT (0.68) | HTTALDH1A1SMN1; SMN2CTBP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| CN-109535017-B | Preparation method of venlafaxine hydrochloride | 合肥立方制药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-03-29 | — | — | US | disclosed |
| US-9784752-B2 | Venlafaxine assay | RANDOX LABORATORIES LIMITED (GB) | 2017-10-10 | — | — | US | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-11-03 | — | — | US | disclosed |
| US-7456317-B2 | Deuterated venlafaxine derivatives; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters; for intravenous administration; tablet/capsule form | AUSPEX PHARMACEUTICALS (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456317-B2 | Deuterated venlafaxine derivatives; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters; for intravenous administration; tablet/capsule form | AUSPEX PHARMACEUTICALS (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2005049560-A2 | PROCESS FOR THE PREPARATION OF ANTI-DEPRESSANT COMPOUND | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
| CN-1240206-A | Process for preparing 1[2-(dimethyamino)-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloridumi | HUADONG SCIENCE & ENGINEERING (CN) | 2000-01-05 | — | — | CN | disclosed |
| US-4761501-A | INTERMEDIATES FOR ANTIDEPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0112669-B1 | PHENETHYLAMINE DERIVATIVES AND INTERMEDIATES THEREFOR | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4611078-A | ANTIDEPRESSANT INTERMEDIATES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| US-4535186-A | CENTRAL NERVOUS SYSTEM ANTIDEPRESSANTS; VENLAFAXINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | HTT 1000/4885ALOX5 3581/4885SIGMAR1 186/4885 |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | HTT 1000/4885ALOX5 3581/4885SIGMAR1 186/4885 |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | SLC6A4, HTR4, OPRK1 | HTT 820/4885ALOX5 1460/4885SIGMAR1 407/4885 |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | HTT 1000/4885ALOX5 3581/4885SIGMAR1 186/4885 |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | HTT 1000/4885ALOX5 3581/4885SIGMAR1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.